mRNA Technology Newsletter
Issue #48August 3, 20267 studies

A new RNA polymerase makes self-amplifying vaccine production 9x easier

mRNA medicine is maturing fast — but the manufacturing pipeline still has some stubborn bottlenecks.

This week's research chips away at several of them, from better enzymes to smarter delivery to a vaccine that protected two elephants from a fatal herpesvirus.

🧬 A Bacterial Virus Enzyme Just Made Self-Amplifying mRNA 9x Easier to Produce

  • Self-amplifying mRNA (saRNA) vaccines can trigger strong immune responses at tiny doses — but they're enormous molecules (~11,500 nucleotides), and the standard T7 enzyme used to manufacture RNA struggles with them badly.
  • Researchers identified an RNA polymerase from Klebsiella phage 32 (KP32) that produces the same long saRNA sequence at 9.3-fold higher yields than T7, while also tolerating a wider range of temperatures, pH levels, and salt concentrations.
  • Crucially, KP32 uses the native AU starting sequence that saRNA requires — a technical constraint T7 doesn't handle well — meaning the output is biologically correct, not just abundant.

Why it matters: Manufacturing saRNA at scale has been one of the quiet blockers of next-generation vaccine development. A drop-in enzyme upgrade that nearly 10x's yield without changing the product is the kind of fix the field has been waiting for.

🥉 Top 5% journal 🔗 RNA (New York, N.Y.) Journal Article 🗓️ Jul 31

Key Findings

🐘 An mRNA Vaccine Kept Two Elephants Healthy During a Normally Fatal Herpesvirus Infection

  • Two juvenile Asian elephants vaccinated against elephant endotheliotropic herpesvirus (EEHV1A) later developed confirmed viral infections — but both stayed clinically healthy, with viral loads staying low and resolving without treatment.
  • Post-infection antibody levels climbed and held, suggesting the vaccine primed a response that contained the virus rather than blocked it entirely.
💡 Vaccinated elephants survived a virus that routinely kills unprotected juveniles.
🔗 Journal of virology Journal Article 🗓️ Jul 28

💉 One Shot for Flu and COVID Worked as Well as Two Separate Vaccines in Adults Over 50

  • In a phase 3 trial of 2,022 adults aged 50+ in Japan, the combo mRNA vaccine mRNA-1083 hit non-inferior immune responses against all tested influenza strains and SARS-CoV-2 compared to licensed individual vaccines.
  • The overall population showed superiority for matched flu strains and COVID, with responses still above baseline at 6 months. No myocarditis or pericarditis cases were reported.
💡 A single-shot flu-COVID combo vaccine matched two separate shots across all key immune measures.
Top 20% journal 🔗 Vaccine Journal Article 🗓️ Jul 30

🫁 A Lung-Targeting mRNA Delivery Strategy Confined 94.5% of Gene Expression to the Lungs

  • By engineering mRNA with microRNA recognition sites that silence expression in the liver, researchers redirected a modified lipid nanoparticle formulation so that 94.5% of total transgene expression landed in the lungs after intravenous injection in mice.
  • The same platform successfully delivered an anti-fibrosis payload that suppressed key markers of lung scarring in human fibroblast cells.
💡 Adding microRNA silencing sequences to mRNA nearly eliminated off-target liver expression.
Top 20% journal 🔗 Pharmaceutics Journal Article 🗓️ Jul 28

🔬 Removing Individual Lipids From Nanoparticles Reveals What Each One Actually Does

  • Stripping cholesterol from lipid nanoparticles (LNPs) eliminated efficient liver delivery but left delivery to other organs intact. Removing the phospholipid didn't change organ targeting but sharply reduced inflammation. Removing PEG-lipid shifted delivery preference toward the spleen.
  • The ionizable lipid remained the primary driver of overall delivery efficiency across all conditions.
💡 Each lipid component controls a distinct function — cholesterol for liver, PEG for spleen tropism.
🥈 Top 2% journal 🔗 ACS nano Journal Article 🗓️ Jul 27

🧊 Empty Nanoparticles Loaded With mRNA After Manufacture Performed as Well as Standard Versions

  • Researchers built empty lipid nanoparticles first, then loaded mRNA into them later by adjusting pH and ethanol levels — a reversal of the standard co-precipitation process.
  • Post-loaded particles stayed under 100 nm, showed comparable mRNA delivery efficiency in HeLa cells, and had similar internal structures to conventionally made LNPs, suggesting the approach could enable point-of-use vaccine assembly with milder storage requirements.
💡 Post-loading mRNA into pre-made nanoparticles matched standard delivery without cold-chain co-manufacturing.

⚠️ COVID mRNA Vaccines Appear to Shift Anti-PEG Antibody Behavior in Vaccinated People

  • An analysis of 325 blood donor samples found that recipients of PEGylated mRNA-LNP vaccines (Comirnaty and Spikevax) showed increased anti-PEG antibody levels and antibodies with higher binding strength toward larger, more complex PEG structures — including PEGylated liposomes.
  • Polysorbate-containing or PEG-free vaccines did not produce comparable shifts, pointing specifically to the LNP-PEG interaction as the driver.
💡 mRNA-LNP vaccines appear to reshape how the immune system recognizes PEG, especially after repeat doses.
Top 20% journal 🔗 Pharmaceutics Journal Article 🗓️ Jul 28

Implications

The week's papers collectively push mRNA medicine toward better manufacturing, smarter tissue targeting, and broader species applications. The unresolved tension: as LNP formulations grow more precise and PEG alternatives remain underdeveloped, the field still lacks consensus on how repeat dosing reshapes immune responses to the delivery vehicle itself — not just the payload.

Studies in this issue

Primary sources used for this newsletter.

  1. Efficient production of a self-copying RNA vaccine using a single enzyme from Klebsiella phage 32 starting with its natural RNA code
    main storyRNA (New York, N.Y.)2026-07-31PMID 42538131
  2. First signs that an mRNA vaccine can protect young elephants naturally infected with EEHV1A
    key findingJournal of virology2026-07-28PMID 42517618
  3. Immune response, side effects, and safety of an mRNA flu and COVID-19 combined vaccine in Japanese adults aged 50 and over
    key findingVaccine2026-07-30PMID 42531981
  4. Immune responses to PEG in mRNA lipid vaccines show changes across the population
    key findingPharmaceutics2026-07-28PMID 42514893
  5. Improving delivery of therapeutic mRNA to the lungs to prevent lung scarring
    key findingPharmaceutics2026-07-28PMID 42514945
  6. Loading RNA into fat-based nanoparticle carriers
    key findingbioRxiv : the preprint server for biology2026-08-01PMID 42539106
  7. Understanding the Roles of Different Parts in mRNA Lipid Nanoparticles
    key findingACS nano2026-07-27PMID 42503852

Continue reading

All mRNA Technology issues